年龄是达到24个月无事件生存的弥漫大B细胞淋巴瘤患者最重要的生存预测因素:一项瑞典人群研究
多因素分析显示仅年龄>60岁显著影响EFS24后的OS。结论:>60岁患者EFS24后应继续随访。
要点
- 仅年龄>60岁显著影响EFS24后OS,>60岁患者应考虑EFS24后继续随访。
核心结论
- 年龄>60岁是达到EFS24后影响OS的最重要因素,此类患者应考虑EFS24后继续随访。
研究设计与样本
- 基于瑞典癌症登记和患者病历的人群研究,纳入五个县2001–2014年1169例成人弥漫大B细胞淋巴瘤患者。
主要发现
- 年龄<60岁患者OS与标准人群匹配。
- 多因素分析中仅年龄>60岁显著影响EFS24后OS(对比标准人群)。
- 早期阶段患者达到EFS12未改善OS。
临床怎么用
- 对年龄>60岁达到EFS24的弥漫大B细胞淋巴瘤患者,应考虑EFS24后继续随访。
- 年龄<60岁达到EFS24的患者OS与标准人群匹配,随访策略可相应调整。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Routine follow-up for diffuse large B-cell lymphoma have been shortened to 2 years when event-free survival at 24 months (EFS24) emerged as a new milestone. In the present study, we aimed to determine whether the achievement of this milestone affected overall survival (OS). We compared OS to that of an age- and sex-matched population, analysed other factors governing OS, and reviewed the causes of death. Data were collected from the Swedish Cancer Registry and from individual patient's records. We included 1169 adult patients from five counties between the years 2001 and 2014. The median (range) age was 64·6 (18-91) years, 56·6% were men and the median follow-up was 82·3 months. For early stages, the achievement of EFS12 did not improve OS. More than two-thirds of the patients (n = 837, 71·6%) achieved EFS24, of which 190 (22·7%) died during follow-up. Lymphoma (20%), cardiovascular disease (22·4%) and malignancies (16%) contributed to causes of death. Patients aged <60 years had an OS that matched the standard population. In multivariate analysis, only age >60 years significantly affected OS after EFS24 compared with the standard population. We concluded that follow-up beyond EFS24 should be considered for patients aged >60 years.
引用
- Abu Sabaa A, Mörth C, Hasselblom S, et al. Age is the most important predictor of survival in diffuse large B-cell lymphoma patients achieving event-free survival at 24 months: a Swedish population-based study. Br J Haematol. 2021. PMID: 33948942. doi:10.1111/bjh.17206
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。